EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Success and Limitations of PSMA RLT : The Nuclear Medicine View

Michael S Hofman

European Urology Focus · 2026-10 · 12 (5) · 827-829

DOI: 10.1016/j.euf.2026.05.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026-10. Verfasst von Michael S Hofman. Beteiligte Einrichtung: Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallu…. Hauptthemen laut MEDLINE: Radioisotopes, Prostatic Neoplasms, Nuclear Medicine, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Gefördert von: NHMRC, Peter MacCallum Cancer Centre, National Imaging Facility.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lutetium-177 PSMA radioligand therapy (RLT) represents a paradigm shift in advanced prostate cancer care, establishing a precision oncology standard through its inherent theranostic capability. From a nuclear medicine perspective, its defining success lies in the ability to precisely select patients and offer targeted cytotoxic delivery of radiation, resulting in high objective response rates and quality-of-life improvements, particularly rapid pain palliation. A collaborative view with medical oncology highlights critical limitations. Despite frequent favourable initial responses, disease recurrence is almost universally inevitable, demonstrating a modest survival benefit in randomised trials and possibly limited control over micrometastatic or heterogeneous disease. The future requires bridging this gap through interdisciplinary research: leveraging molecular imaging for adaptive treatment strategies, evaluating earlier-line use, and developing synergistic combinations and next-generation isotopes, including Auger/conversion electron and alpha emitters, to maximise clinical benefit and achieve durable responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadioisotopesProstatic NeoplasmsNuclear MedicineRadiopharmaceuticalsLutetiumGlutamate Carboxypeptidase IIAntigens, SurfaceHumansMaleQuality of Life

Substanzen

RadioisotopesRadiopharmaceuticalsLutetiumLutetium-177Glutamate Carboxypeptidase IIAntigens, SurfaceFOLH1 protein, human

Autor:innen und Institutionen

  • Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC), Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Aus…

Förderung

  • NHMRC
  • Peter MacCallum Cancer Centre
  • National Imaging Facility
  • Peter MacCallum Foundation
  • Prostate Cancer Foundation
  • University of Melbourne
  • Australian Cancer Research Foundation

Zitieren

APA

Hofman, M. S. (2026). Success and Limitations of PSMA RLT : The Nuclear Medicine View. European Urology Focus, 12(5), 827-829. https://doi.org/10.1016/j.euf.2026.05.016

Vancouver

Hofman MS. Success and Limitations of PSMA RLT : The Nuclear Medicine View. European Urology Focus. 2026;12(5):827-829. doi:10.1016/j.euf.2026.05.016

BibTeX
@article{Hofman2026,
  author = {Hofman, Michael S},
  title = {Success and Limitations of PSMA RLT : The Nuclear Medicine View},
  journal = {European Urology Focus},
  year = {2026},
  volume = {12},
  number = {5},
  pages = {827--829},
  doi = {10.1016/j.euf.2026.05.016}
}
Kostenlos starten →